Literature DB >> 28969220

Pregnancy Outcomes in Isolated Oligohydramnios during Second Trimester: A Case Series.

Ashima Taneja1, Kamaldeep Arora2, Isha Chopra3, Sushree Samiksha Naik4.   

Abstract

Oligohydramnios is associated with increased maternal and foetal morbidities. However, some of the recent studies have shown no adverse effect of isolated oligohydramnios on perinatal outcome and recommends continuation of pregnancy. Pregnancies between 18-28 weeks with isolated Oligohydramnios were included. History and physical examination was recorded in a pre-designed proforma. All the cases received care as per the protocol. A total of seven patients were recruited of which one was a twin pregnancy with Oligohydramnios in both sacs. The mean age at presentation was 30 years. Three patients went into spontaneous explusion at an average gestational age of 22-24 weeks. One patient with twins delivered vaginally at 32 weeks. Rest were delivered by caesarean section between 34-35 weeks (indication in majority of the cases was foetal distress and cord compression). None of the babies suffered any complication and were discharged in good condition. Isolated oligohydramnios during second trimester does not increase adverse perinatal outcome significantly (but increases the caesarean section rate) and therefore, should not be an indication for termination of pregnancy.

Entities:  

Keywords:  Caesarean; Morbidity; Mortality; Newborn

Year:  2017        PMID: 28969220      PMCID: PMC5620861          DOI: 10.7860/JCDR/2017/27722.10502

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  11 in total

1.  Short-term outcome among term singleton infants with intrapartum oligohydramnios.

Authors:  Leah Leibovitch; Jacob Kuint; Elkana Rosenfeld; Irit Schushan-Eisen; Alina Weissmann-Brenner; Ayala Maayan-Metzger
Journal:  Acta Paediatr       Date:  2012-04-04       Impact factor: 2.299

2.  Influence of oligohydramnios on preterm premature rupture of the membranes at 30 to 36 weeks' gestation.

Authors:  Jillian Coolen; Koichi Kabayashi; Karen Wong; Damon C Mayes; Nancy Bott; Nestor Demianczuk
Journal:  J Obstet Gynaecol Can       Date:  2010-11

3.  Perinatal outcomes with isolated oligohydramnios at term pregnancy.

Authors:  Mariña Naveiro-Fuentes; Alberto Puertas Prieto; Rocío Sánchez Ruíz; María Paz Carrillo Badillo; Francisco Montoya Ventoso; José Luis Gallo Vallejo
Journal:  J Perinat Med       Date:  2016-10-01       Impact factor: 1.901

4.  Isolated oligohydramnios is not an indicator for adverse perinatal outcome.

Authors:  Hina Ahmad; Shama Munim
Journal:  J Pak Med Assoc       Date:  2009-10       Impact factor: 0.781

5.  The amniotic fluid index in normal human pregnancy.

Authors:  T R Moore; J E Cayle
Journal:  Am J Obstet Gynecol       Date:  1990-05       Impact factor: 8.661

Review 6.  Severe midtrimester oligohydramnios: treatment strategies.

Authors:  Zoltan Kozinszky; János Sikovanyecz; Norbert Pásztor
Journal:  Curr Opin Obstet Gynecol       Date:  2014-04       Impact factor: 1.927

7.  Assessing the optimal definition of oligohydramnios associated with adverse neonatal outcomes.

Authors:  Anthony Shanks; Methodius Tuuli; Caren Schaecher; Anthony O Odibo; Roxane Rampersad
Journal:  J Ultrasound Med       Date:  2011-03       Impact factor: 2.153

8.  Isolated oligohydramnios is not associated with adverse perinatal outcomes.

Authors:  Jun Zhang; James Troendle; Susan Meikle; Mark A Klebanoff; William F Rayburn
Journal:  BJOG       Date:  2004-03       Impact factor: 6.531

9.  A prospective clinical study of feto-maternal outcome in pregnancies with abnormal liquor volume.

Authors:  Gita Guin; Shweta Punekar; Arvind Lele; Shashi Khare
Journal:  J Obstet Gynaecol India       Date:  2012-02-09

Review 10.  Association and prediction of amniotic fluid measurements for adverse pregnancy outcome: systematic review and meta-analysis.

Authors:  R K Morris; C H Meller; J Tamblyn; G M Malin; R D Riley; M D Kilby; S C Robson; K S Khan
Journal:  BJOG       Date:  2014-02-07       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.